

# BMJ Open

## Magnetic Resonance Imaging-based Comparative Research in Different Mild Cognitive Impairment Subtype: Study Protocol of an Observational Case-Control Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013432
Article Type:	Protocol
Date Submitted by the Author:	12-Jul-2016
Complete List of Authors:	Yu, Yang; Hongqi Hospital of Mudanjiang Medical University, Department of Neurology Zhao, Weina; Hongqi Hospital of Mudanjiang Medical University, Department of Neurology Li, Siou; Hongqi Hospital of Mudanjiang Medical University, Department of Neurology Yin, Changhao ; Hongqi Hospital of Mudanjiang Medical University, Department of Neurology
<b>Primary Subject Heading</b>:	Neurology
Secondary Subject Heading:	Neurology
Keywords:	Amnesic mild cognitive impairment, ascular mild cognitive impairment, Neuropsychological, Neuroimaging techniques

SCHOLARONE™  
Manuscripts

Only

Magnetic Resonance Imaging-based Comparative Research in Different  
Mild Cognitive Impairment Subtype: Study Protocol of an Observational  
Case-Control Study

Authors: Yang Yu, Weina Zhao, Siou Li, \*Changhao Yin

Corresponding author:

Changhao Yin

Hongqi Hospital of Mudanjiang Medical Universiy

No.3 TongXiang St., AiMin District, Mudanjiang, Heilongjiang Province,  
157011

yinchanghao7916@sina.com

Yang Yu, Department of Neurology, Hongqi Hospital of Mudanjiang  
Medical Universiy, Mudanjiang, Heilongjiang, China

Weina Zhao, Department of Neurology, Hongqi Hospital of Mudanjiang  
Medical Universiy, Mudanjiang, Heilongjiang, China

Siou Li, Department of Neurology, Hongqi Hospital of Mudanjiang  
Medical Universiy, Mudanjiang, Heilongjiang, China

Word count: 2563

## Abstract

### Introduction:

Amnesic mild cognitive impairment (aMCI) and vascular mild cognitive  
impairment (VaMCI) are the two main types of mild cognitive

1  
2  
3  
4 impairment (MCI), one would probably progress to Alzheimer's disease  
5  
6 (AD) and the other is likely to be vascular dementia. The brain structure  
7  
8 and function are different from normal elders. However, whether this two  
9  
10 MCI are different in brain structure hasn't been detected. This study is  
11  
12 designed to analysis the brain neuroimage in VaMCI and Amci with  
13  
14 multi-modality magnetic resonance imaging (structural MRI, function  
15  
16 MRI and diffusion tensor imaging).

### 21 **Methods and analysis:**

22  
23 In this study, 80 subjects who are diagnosed as aMCI and 80 VaMCI will  
24  
25 be recruited at the Hongqi Hospital of Mudanjiang Medical University,  
26  
27 Heilongjiang, China. All subjects will undergo the neuroimaging and  
28  
29 neuropsychological evaluation. The primary outcome measures are 1)  
30  
31 Microstructural alterations revealed with multimodal MRI scans  
32  
33 including structure MRI (sMRI), resting state functional MRI (rs-fMRI),  
34  
35 diffusion tensor imaging (DTI); 2) neuropsychological evaluation,  
36  
37 including Auditory Verbal Learning Test (AVLT), mini-mental state  
38  
39 examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical  
40  
41 Dementia Rating scale (CDR).

### 48 **Ethics and Dissemination:**

49  
50 Ethical approval of this has been obtained from the medical research  
51  
52 ethics committee and institutional review board of Hongqi Hospital of  
53  
54 Mudanjiang Medical University, Heilongjiang, China. Study findings will  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 be disseminated widely through conference presentations and  
5  
6 peer-reviewed publications.  
7

### 8 9 **Trial Registration:**

10 Protocol Registered on ClinicalTrials.gov (NCT02706210)

11  
12  
13 **Keywords:** Amnestic mild cognitive impairment, Vascular mild cognitive  
14  
15 impairment, Neuropsychological, Neuroimaging techniques,  
16  
17  
18

### 19 20 21 **Introduction**

22  
23 As people live longer, so chronic diseases become more prevalent.  
24  
25 Dementia is a progressive brain disease, which is one of the main chronic  
26  
27 non-communicable diseases associated with disability and mortality  
28  
29 among elderly individuals. Dementia resulting from Alzheimer's disease  
30  
31 (AD) has catapulted into the public's consciousness while dementia has  
32  
33 many causes—not just Alzheimer's, vascular dementia (VD) is also  
34  
35 considered to be the main types of dementia. Mild cognitive impairment  
36  
37 (MCI) constitutes an intermediate stage between normal aging and  
38  
39 dementia<sup>1</sup>. A widely shared view is that future treatment strategies need to  
40  
41 focus on treatment of the MCI.  
42  
43  
44  
45  
46  
47

48  
49 Amnestic MCI (aMCI) has been reported to be the clinical transition  
50  
51 stage of AD<sup>2</sup> and vascular MCI (VaMCI) is considered to be the early  
52  
53 stage of VD<sup>3 4</sup>. The pathogenesis of the two diseases are different, the  
54  
55 aMCI is considered to be neurodegenerative disease caused by the  
56  
57  
58  
59  
60

1  
2  
3  
4 endogenous neuronal factors such as tau and amyloid pathology<sup>5</sup> while  
5  
6 VaMCI is caused by vascular diseases such as infarcts or profuse white  
7  
8 matter disease<sup>3 6</sup>. Both VaMCI and aMCI are associated with deficits in  
9  
10 multiple cognitive domains, with the same chief complaints in memory  
11  
12 deficits<sup>7 8</sup>. A considerable body of literature has concluded that patients  
13  
14 with VaMCI generally shows more impairment in semantic memory,  
15  
16 executive/attentional functioning, and visual-spatial and perceptual skills,  
17  
18 whereas the clinical picture of AD is characterized by deficits in episodic  
19  
20 memory<sup>3 9 10</sup>. Under some specific neuropsychological tests, they may  
21  
22 have different performances. However, few studies have examined the  
23  
24 relationship between these two kinds of MCI in their brain structural and  
25  
26 cognitive behavior. If it can be clear which will turn into what type of  
27  
28 dementia in patients with cognitive impairment stage, it may be helpful to  
29  
30 the understanding of the mechanism of the two MCI.  
31  
32

33  
34 According to previous publications, aMCI and VaMCI are considered to  
35  
36 be a kind of “disconnection syndrome”<sup>11 12</sup>. By applying the structural  
37  
38 magnetic resonance imaging (sMRI), resting state functional magnetic  
39  
40 resonance (fMRI) and diffusion tensor magnetic resonance imaging (DTI)  
41  
42 technology, the project comprehensive analysis comparison of brain  
43  
44 structure and function in patients with aMCI and VaMCI. Previous  
45  
46 studies have detected the atrophy of brain volume, reduced white matter  
47  
48 integrity and abnormal functional connectivity in those MCI patients<sup>13-17</sup>.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Previous studies also have detected that the brain structures impaired in  
5  
6 VD seem not consistent with AD<sup>18 19</sup>, but whether they are different in  
7  
8 MCI hasn't been detected. Moreover, the changes in brain structural and  
9  
10 function are not completely similar<sup>20-22</sup>. Unlike using a single technique,  
11  
12 by using multimodal magnetic resonance, the brain structure and function  
13  
14 can be analyzed omni-directionally and multi-angularly. By using  
15  
16 multimodal magnetic resonance could also consolidate our understanding  
17  
18 of how functional networks interact with their structural substrates.  
19  
20

21  
22 This project in order to reveal the cognitive impairment disease neural  
23  
24 circuits in the development of the network connection and its change rule.  
25  
26

27  
28 People can further understand the pathogenesis of cognitive impairment,  
29  
30 discover the relationship between brain structure, function and cognitive  
31  
32 behavior.  
33  
34

## 35 36 **Methods**

### 37 38 **Subject**

39  
40 The recruited patients were patients (inpatients and/or outpatients) who  
41  
42 were registered at the Neurology Department of Hongqi Hospital of  
43  
44 Mudanjiang Medical University, Heilongjiang, China. All participants  
45  
46 received baseline evaluation, including complete sociodemographic and  
47  
48 clinical data collection. Patient histories were collected from informants,  
49  
50 usually from their spouses or children. The diagnosis for the two groups  
51  
52 was performed by two experienced neurologists, respectively. This study  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 was approved by the medical research ethics committee and the  
5  
6 institutional review board of Hongqi Hospital of Mudanjiang Medical  
7  
8 University, Heilongjiang, China. The study was conducted in accordance  
9  
10 with the approved guidelines. Written informed consent was obtained  
11  
12 from all participants.  
13  
14

## 15 16 17 **Inclusion Criteria**

### 18 19 20 **Criteria for aMCI**

21  
22  
23 Diagnosis of aMCI was made based on the recent international consensus  
24  
25 criteria, which were adapted as follows<sup>1 3 23-25</sup>: 1) subjective cognitive  
26  
27 complaints reported by the informant; 2) objective cognitive impairments  
28  
29 that do not meet the Diagnostic and Statistical Manual of Mental  
30  
31 Disorders (DSM-IV-R, fourth-revised edition) criteria for dementia; 3)  
32  
33 normal or near-normal performance of general cognitive functioning and  
34  
35 no or minimum impairments in daily life activities; 4) abnormal memory  
36  
37 function, documented by extensive neuropsychological evaluation;  
38  
39 normal general cognitive function, Clinical Dementia Rating Scale (CDR)  
40  
41 score = 0.5; 5) Hippocampal atrophy confirmed by structural MRI was  
42  
43 met simultaneously in the aMCI group<sup>1</sup>. 6) Neuropsychological testing  
44  
45 included a Hanchinski ischemic (HIS) score (HIS score  $\leq$  to 4) and  
46  
47 Montreal cognitive assessment score (MoCA, Beijing Version)<sup>26</sup>.  
48  
49  
50  
51  
52  
53  
54

### 55 56 57 **Criteria for VaMCI**

58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Diagnosis of VaMCI depended on the following criteria<sup>1 3 17 26</sup>: 1) subjective cognitive complaints reported by the participant or his/her caregiver; 2) insufficient cognitive impairment to meet the DSM-IV-R criteria for dementia; vascular etiology as follows: cognitive impairment due to subcortical small vessel disease (SIVD) was defined as moderate white matter changes (at least 1 region score <2 according to the Wahlund rating scale), and/or multiple lacunar infarcts (<2) on brain imaging. And may or not be suggested by minor neurological signs (such as hemiparesis, lower facial weakness, Babinski sign, sensory deficit, dysarthria, gait disorder, urine urgency, or motor slowness). Neuropsychological testings for aMCI, the MoCA scoring, and HIS determination ( $HIS \geq 7$ ) were also performed.

### Exclusion Criteria

Participants were excluded if they had the following: 1) psychiatric disease (eg, depression, Hamilton depression rating scale >20, Center for Epidemiologic Studies Depression Scale >21), systemic disease (eg, brain tumor, Parkinson disease, encephalitis or epilepsy) or other neurological disorder, 2) visual or auditory abnormalities, severe aphasia or palsy that made clinical assessments infeasible; 3) any medical or psychological conditions that might interfere with clinical and neuropsychological assessment, 4) insufficient Mandarin language abilities to complete the assessment.



1  
2  
3  
4 The exclusive criteria for VaMCI also included the following: 1) signs of  
5 large vascular disease, such as cortical, and/or cortico-subcortical, or  
6 non-lacunar territorial infarcts and watershed infarcts or hemorrhages, 2)  
7  
8 patients who may also be considered as aMCI. For aMCI, participants,  
9 those who were considered as VaMCI were excluded. This selection  
10 procedure was applied to ensure the purity of each group.  
11  
12  
13  
14  
15  
16  
17  
18

### 19 **Neuropsychological Evaluations**

20  
21 All participants received a battery of neuropsychological tests to assess  
22 general mental status and other cognitive domains. These tests included  
23 the CDR scale<sup>1 25</sup>, the Mini-Mental State Examination (MMSE)<sup>27</sup>, the  
24 Montreal Cognitive Assessment (MoCA)<sup>26</sup>, and the Auditory Verbal  
25 Learning Test (AVLT)<sup>28</sup>, and also Hamilton Depression Scale (HAMD)<sup>29</sup>.  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 **Magnetic resonance brain imaging Imaging protocol**

36  
37 For each participant, conventional brain T1-weighted (T1WI),  
38 T2-weighted (T2WI) will be obtained to exclude serious brain diseases.  
39  
40 For inpatients, the data will be collected at Hongqi Hospital of  
41 Mudanjiang Medical University while for outpatients, the T1WI and  
42 T2WI may be acquired from other hospitals. The imaging data for  
43 analyzing will be acquired using a 3.0 T Trio Siemens scanner at Hongqi  
44 Hospital of Mudanjiang Medical University.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

### 55 **sMRI**

Using a sagittal MP-RAGE sequence with the following imaging parameters: TR = 1900 ms; TE = 2.2 ms; inversion time = 900 ms; flip angle = 9°; FOV = 256 mm × 256 mm; matrix = 256 × 256; 176 slices, thickness = 1.0 mm.

MRI data acquisition was performed on a 3.0 T Siemens scanner by employing a sagittal magnetization-prepared rapid gradient echo (MP-RAGE) sequence with the following imaging parameters: repetition time (TR) = 1900 ms; echo time (TE) = 2.2 ms; inversion time = 900 ms; flip angle = 90°; field of view (FOV) = 250 mm × 250 mm; matrix = 256 × 256; 176 slices, thickness = 1.0 mm. Brain MR images were inspected by an experienced neuroradiologist, and no gross abnormalities were observed for any subject.

### **fMRI**

Using an echo-planar imaging sequence with the following parameters: repetition time (TR) = 2000 ms, echo time (TE) = 40 ms, flip angle (FA) = 90°, number of slices = 28, slice thickness = 4 mm, gap = 1 mm, voxel size = 4 × 4 × 4 mm<sup>3</sup>, and matrix = 64 × 64. Participants will be asked to lie quietly in the scanner with their eyes closed during data acquisition. Each scan lasted for 478 s.

### **DTI**

Using an echo planar imaging (EPI) sequence in 32 independent, non-collinear directions of a b-value = 1000 s/mm<sup>2</sup>, and one additional

1  
2  
3  
4 image with no diffusion weighting ( $b = 0$ ). TR = 11000 ms, TE = 98 ms,  
5  
6 flip angle =  $90^\circ$ , field of view (FOV) = 256 mm  $\times$  256 mm, imaging  
7  
8 matrix = 128  $\times$  128, number of slices = 60, and slice thickness = 2 mm.  
9  
10  
11 Three acquisitions will be averaged to increase the signal-to-noise ratio.  
12

13  
14 MRI image analysis

### 15 16 **sMRI data analysis**

17  
18 Both the cortical reconstruction and morphological features extraction  
19  
20 will be obtained by using the FreeSurfer software  
21  
22 (<http://surfer.nmr.mgh.harvard.edu/>) with a standard cortical automatic  
23  
24 handling protocol. First, the data will be normalized to a standard  
25  
26 anatomical template<sup>30</sup> and corrected for bias-field inhomogeneity.  
27  
28 Subsequently, the images will be skull-stripped using a watershed  
29  
30 algorithm<sup>31</sup> and subsequently segmented into subcortical white matter and  
31  
32 deep gray matter volumetric structures<sup>32 33</sup>. The initial tessellation will be  
33  
34 formed by reconstructing the boundary of gray matter/white matter (white  
35  
36 surface) and the outer cortical surface (pial surface)<sup>34 35</sup>. After that, a  
37  
38 series of deformable procedures will be performed. All reconstructed  
39  
40 surfaces will be visually inspected for gross-anatomical topological  
41  
42 defects. Finally, a variety of morphological features at each vertex on the  
43  
44 pial surface will be computed.  
45  
46  
47  
48  
49  
50  
51  
52

### 53 54 **fMRI data analysis**

55  
56 Image preprocessing will be performed by using SPM8  
57  
58  
59  
60

(<http://www.fil.ion.ucl.ac.uk/spm/>) and Data Processing Assistant for Resting-State fMRI. The preprocessing procedures will be performed including removal of the first 10 volumes, slice timing, and head motion correction. All fMRI data will be satisfied the criteria of spatial movement in any direction  $< 3$  mm or  $3^\circ$  and the subjects will be demonstrated no significant group differences in the head motion parameters (i.e, three translation and three rotation parameters). To normalize the fMRI data spatially, the T1-weighted images will be firstly registered to the mean functional data, and the resulting aligned T1 data set will be segmented and transformed into MNI space using the DARTEL toolbox, and a group template will be generated. Next, the motion corrected functional volumes will be specially normalized to the group template using the transfer parameter estimated by DARTEL segmentation and resampled to 3 mm isotropic voxels. Further, the functional images will be spatially smoothed with a 4 mm Gaussian kernel. The linear detrend and temporal bandpass filtering (0.01 – 0.08 Hz) will be performed to reduce the influences of low frequency drift and high-frequency physiological noise. Finally, several nuisance signals will be regressed out from the data, including the six motion parameters, the global, the white matter, and the cerebrospinal fluid signals. Functional connectivity (FC) analysis using DPARSF software (<http://www.restfmri.net/forum/DPARSF>).

## DTI data analysis

DTI data processing will be carried out using FSL software (FMRIB Software Library, <http://www.fmrib.ox.ac.uk/fsl>). Initially, eddy current correction will be run to correct gradient-coil distortions and small-head motions using affine registration to a reference image (b0 volume). The brain voxels of DTI data will be extracted using the Brain Extraction Tool (BET). The maps of diffusion tensor parameters including fractional anisotropy (FA), axial diffusivity (DA), radial diffusivity (DR), and mean diffusivity (MD) will be calculated using DTI-FIT tool, which fits a diffusion tensor model to diffusion-weighted images for each voxel. Voxel-wise statistical analysis of the FA, DA, DR, and MD data will be performed for regional differences using tract-based spatial statistics (TBSS).

## Association between neuroimage and neuropsychological performance

Analysis the interaction between the parameters acquired by multimodal magnetic resonance and cognition measures.

The scheme of the current prospective trial is described in Fig. 1

## Discussion

In the published paper works, the researchers usually focus on the differences between patients and normal elders, little pays attention to the differences between the similar diseases. At the stage of dementia, the

1  
2  
3  
4 white matter microstructure has been detected different between VD and  
5  
6 AD<sup>18</sup>. While it is uncertain that the differences took place in the stage of  
7  
8 dementia or earlier. A study has demonstrated that the hippocampus  
9  
10 structure is different in aMCI and VaMCI<sup>36</sup>. But what about other parts of  
11  
12 gray matters hasn't been detected. And by using neuropsychological tests,  
13  
14 previous study has observed the mode of memory deficit in aMCI and  
15  
16 VaMCI is also different<sup>8</sup>. However, there is lack of evidence to compare  
17  
18 the relationship between those abnormal cognitive behaviors and brain  
19  
20 structure. So it is meaningful to use multimodal magnetic resonance to  
21  
22 observe the neuroimage in the two subtypes of MCI.  
23  
24  
25  
26  
27

28  
29 Some limitations have to be took into account about this study. First, the  
30  
31 trial is just an observational study without follow up so whether would  
32  
33 they convert to AD or VD in the future is uncertain. Therefore, we will  
34  
35 plan to apply a follow-up to track the dynamic evolution of these patients.  
36  
37  
38 Second, our hospital is a primary hospital, we don't have a PET to raise  
39  
40 the precision of diagnosis. But the diagnosis of the two groups follow the  
41  
42 criteria for the diseases critically to make the diagnosis as precisely as  
43  
44 possible. And we will plan to gather the blood and cerebrospinal fluid in  
45  
46 our future designs.  
47  
48  
49

50  
51 The purpose for this study is to find out the differences in neuroimaging  
52  
53 between aMCI and VaMCI and exploring the possible mechanism of the  
54  
55 cognitive disorders in the two diseases. Moreover, to provide scientific  
56  
57  
58  
59  
60

1  
2  
3  
4 diagnosis evidence for different subtypes of MCI.

5  
6  
7 **Ethics approval and consent to participate**

8  
9 Ethical approval of this has been obtained from the medical research  
10  
11 ethics committee and institutional review board of Hongqi Hospital of  
12  
13 Mudanjiang Medical University, Heilongjiang, China. All participation is  
14  
15 based on written informed consent and the participants will be able to  
16  
17 withdraw from the study at any time.  
18  
19

20  
21 **Consent for publication**

22  
23 Written consent is obtained from each subject before publishing in this  
24  
25 study.  
26  
27

28  
29 **Availability of data and material**

30  
31 Not applicable.  
32  
33

34  
35 **Funding**

36  
37 Study Funded by the National Natural Science Funds of China (Grant No.  
38  
39 81301188)  
40

41  
42 **Author Contributions**

43  
44 All authors participated in the design of the study. YY drafted the  
45  
46 manuscript. YCH is supervising the project and made critical revision of  
47  
48 the manuscript for important intellectual content. All authors read and  
49  
50 approved the final manuscript.  
51  
52

53  
54 **Competing interests**

55  
56 All authors report no competing interests.  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-013432 on 8 March 2017. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.






Fig 1 Flowchart of the current prospective diagnostic trial

1. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med* 2004;**256**(3):183-94.
2. Hussain H. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. *Neurology* 2007;**68**(4):409-09.
3. Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. *Alzheimer Dis Assoc Disord* 2014;**28**(3):206-18.
4. Jin-zhou T, Heng-ge X, Bin Q, et al. Guidelines for the Diagnosis of Vascular Mild Cognitive Impairment in China. *Chinese Journal of Internal Medicine* 2016;**55**(3):249-56.
5. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. *Nat Cell Biol* 2004;**6**(11):1054-61.
6. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. *Stroke* 2011;**42**(9):2672-713.
7. Parikh PK, Troyer AK, Maione AM, et al. The Impact of Memory Change on Daily Life in Normal Aging and Mild Cognitive

- 1  
2  
3  
4 Impairment. *Gerontologist* 2015.
- 5  
6 8. Zhou A, Jia J. Different cognitive profiles between mild cognitive  
7  
8 impairment due to cerebral small vessel disease and mild cognitive  
9  
10 impairment of Alzheimer's disease origin. *Journal of the*  
11  
12 *International Neuropsychological Society* 2009;**15**(06):898.
- 13  
14  
15 9. Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in  
16  
17 Alzheimer's disease and subcortical vascular dementia. *J Neurol*  
18  
19 *Neurosurg Psychiatry* 2004;**75**(1):61-71.
- 20  
21  
22  
23 10. Tomadesso C, Perrotin A, Mutlu J, et al. Brain structural, functional,  
24  
25 and cognitive correlates of recent versus remote autobiographical  
26  
27 memories in amnesic Mild Cognitive Impairment. *Neuroimage*  
28  
29 *Clin* 2015;**8**:473-82.
- 30  
31  
32  
33 11. Nowrangi MA, Lyketsos CG, Leoutsakos JM, et al. Longitudinal,  
34  
35 region-specific course of diffusion tensor imaging measures in mild  
36  
37 cognitive impairment and Alzheimer's disease. *Alzheimers Dement*  
38  
39 2013;**9**(5):519-28.
- 40  
41  
42  
43 12. O'Sullivan M. Diffusion tensor MRI correlates with executive  
44  
45 dysfunction in patients with ischaemic leukoaraiosis. *Journal of*  
46  
47 *Neurology, Neurosurgery & Psychiatry* 2004;**75**(3):441-47.
- 48  
49  
50  
51 13. Bai F, Xie C, Watson DR, et al. Aberrant hippocampal subregion  
52  
53 networks associated with the classifications of aMCI subjects: a  
54  
55 longitudinal resting-state study. *PLoS One* 2011;**6**(12):e29288.
- 56  
57  
58  
59  
60

- 1  
2  
3  
4 14. Liu J, Yin C, Xia S, et al. White matter changes in patients with  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
15. Li X, Li D, Li Q, et al. Hippocampal subfield volumetry in patients  
with subcortical vascular mild cognitive impairment. *Sci Rep*  
2016;**6**:20873.
16. Lin L, Xue Y, Duan Q, et al. Microstructural White Matter  
Abnormalities and Cognitive Dysfunction in Subcortical Ischemic  
Vascular Disease: an Atlas-Based Diffusion Tensor Analysis Study.  
*J Mol Neurosci* 2015;**56**(2):363-70.
17. Yi L, Wang J, Jia L, et al. Structural and functional changes in  
subcortical vascular mild cognitive impairment: a combined  
voxel-based morphometry and resting-state fMRI study. *PLoS One*  
2012;**7**(9):e44758.
18. Zarei M, Damoiseaux JS, Morgese C, et al. Regional white matter  
integrity differentiates between vascular dementia and Alzheimer  
disease. *Stroke* 2009;**40**(3):773-9.
19. Fu JL, Zhang T, Chang C, et al. The value of diffusion tensor imaging  
in the differential diagnosis of subcortical ischemic vascular  
dementia and Alzheimer's disease in patients with only mild white  
matter alterations on T2-weighted images. *Acta Radiol*  
2012;**53**(3):312-7.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
20. Bai F, Shu N, Yuan Y, et al. Topologically convergent and divergent structural connectivity patterns between patients with remitted geriatric depression and amnesic mild cognitive impairment. *J Neurosci* 2012;**32**(12):4307-18.
21. Zhang J, Wang J, Wu Q, et al. Disrupted brain connectivity networks in drug-naive, first-episode major depressive disorder. *Biol Psychiatry* 2011;**70**(4):334-42.
22. Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. *Nat Rev Neurosci* 2009;**10**(3):186-98.
23. Bowler JV. Modern concept of vascular cognitive impairment. *British Medical Bulletin* 2007;**83**(1):291-305.
24. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. *J Neural Transm Suppl* 2000;**59**:23-30.
25. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology* 1993;**43**(11):2412-4.
26. Lu J, Li D, Li F, et al. Montreal Cognitive Assessment in Detecting Cognitive Impairment in Chinese Elderly Individuals: A Population-Based Study. *Journal of Geriatric Psychiatry and Neurology* 2012;**24**(4):184-90.
27. Zhang Z, Hong X, Hui LI. The minimal state examination in the

- Chinese residents population aged 55 years and over in the urban and rural areas of Beijing. Chinese Journal of Neurology 1999.
28. Delis D. C KJHK. *California Verbal Learning Test: Adult Version Manual*. San Antonio, Tex, USA: The Psychological Corporation, 1987.
29. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960;**23**:56-62.
30. Talairach JJ, Tournoux P. *Co-Planar Stereotaxic Atlas of the Human Brain.3-Dimensional Proportional System: An Approach to Cerebral Imaging*. 1988.
31. Ségonne F, Dale AM, Busa E, et al. A hybrid approach to the skull stripping problem in MRI. *Neuroimage* 2004;**22**(3):1060-75.
32. Fischl B, Salat DH, Busa E, et al. Whole Brain Segmentation : Automated Labeling of Neuroanatomical Structures in the Human Brain. *Neuron* 2002;**volume 33**(3):341-55(15).
33. Fischl B, Van dKA, Destrieux C, et al. Automatically parcellating the human cerebral cortex. *Cerebral Cortex* 2004;**14**(1):11-22.
34. Dale AM, Fischl B, Sereno MI. Cortical Surface-Based Analysis ☆ : I. Segmentation and Surface Reconstruction. *Neuroimage* 1999;**9**(2):179-94.
35. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. *Proceedings of the*

1  
2  
3  
4 National Academy of Sciences of the United States of America  
5  
6 2000;**97**(20):11050-5.  
7

- 8  
9 36. Li X, Li D, Li Q, et al. Hippocampal subfield volumetry in patients  
10  
11 with subcortical vascular mild cognitive impairment. Scientific  
12  
13 Reports 2016;**6**.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Magnetic Resonance Imaging-based Comparative Research in Different Mild Cognitive Impairment Subtype: Study Protocol of an Observational Case-Control Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013432.R1
Article Type:	Protocol
Date Submitted by the Author:	27-Oct-2016
Complete List of Authors:	Yu, Yang; Hongqi Hospital of Mudanjiang Medical University, Department of Neurology Zhao, Weina; Hongqi Hospital of Mudanjiang Medical University, Department of Neurology Li, Siou; Hongqi Hospital of Mudanjiang Medical University, Department of Neurology Yin, Changhao ; Hongqi Hospital of Mudanjiang Medical University, Department of Neurology
<b>Primary Subject Heading</b>:	Neurology
Secondary Subject Heading:	Neurology
Keywords:	Amnesic mild cognitive impairment, Neuropsychological, Neuroimaging techniques, Vascular mild cognitive impairment

SCHOLARONE™  
Manuscripts

Only



Magnetic Resonance Imaging-based Comparative Research in Different  
Mild Cognitive Impairment Subtype: Study Protocol of an Observational  
Case-Control Study

Authors: Yang Yu, Weina Zhao, Siou Li, \*Changhao Yin

Corresponding author:

Changhao Yin

Hongqi Hospital of Mudanjiang Medical Universiy

No.3 TongXiang St., AiMin District, Mudanjiang, Heilongjiang Province,  
157011

yinchanghao7916@sina.com

Yang Yu, Department of Neurology, Hongqi Hospital of Mudanjiang  
Medical Universiy, Mudanjiang, Heilongjiang, China

Weina Zhao, Department of Neurology, Hongqi Hospital of Mudanjiang  
Medical Universiy, Mudanjiang, Heilongjiang, China

Siou Li, Department of Neurology, Hongqi Hospital of Mudanjiang  
Medical Universiy, Mudanjiang, Heilongjiang, China

Word count: 2938

## Abstract

### Introduction:

Amnesic mild cognitive impairment (aMCI) and vascular mild cognitive  
impairment (VaMCI) are the two main types of mild cognitive

1  
2  
3  
4 impairment (MCI), one would probably progress to Alzheimer's disease  
5  
6 (AD) and the other is likely to be vascular dementia (VD). The brain  
7  
8 structure and function of MCI are different from normal elders. However,  
9  
10 whether this two MCI are different in brain structure hasn't been detected.  
11  
12 This study is designed to analysis the brain neuroimage in VaMCI and  
13  
14 aMCI with multi-modality magnetic resonance imaging (structural MRI,  
15  
16 function MRI and diffusion tensor imaging).  
17  
18  
19

### 20 21 **Methods and analysis:**

22  
23 In this study, 80 subjects who are diagnosed as aMCI and 80 VaMCI and  
24  
25 80 age, gender and education matched normal controls (NC) will be  
26  
27 recruited at the Hongqi Hospital of Mudanjiang Medical University,  
28  
29 Heilongjiang, China. All subjects will undergo the neuroimaging and  
30  
31 neuropsychological evaluation. The primary outcome measures are 1)  
32  
33 Microstructural alterations revealed with multimodal MRI scans  
34  
35 including structure MRI (sMRI), resting state functional MRI (rs-fMRI),  
36  
37 diffusion tensor imaging (DTI); 2) neuropsychological evaluation,  
38  
39 including mini-mental state examination (MMSE), Montreal Cognitive  
40  
41 Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Memory  
42  
43 and Executive Screening (MES), trail making test(TMT), the Stroop color  
44  
45 naming condition, Clinical Dementia Rating scale (CDR), for the purpose  
46  
47 of evaluating the global cognition, memory function, attention,  
48  
49 visuospatial skills, processing speed, executive function, and emotion,  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 respectively.

5  
6 **Trial Registration:**

7  
8 Protocol Registered on ClinicalTrials.gov (NCT02706210)

9  
10  
11 **Keywords:** Amnestic mild cognitive impairment, Vascular mild cognitive  
12 impairment, Neuropsychological, Neuroimaging techniques,  
13  
14

15  
16 **Strengths and limitations of this study**

17  
18 Compare different subtypes of MCI.

19  
20 Using a combination of multi-modal imaging.

21  
22 Lack of Clinicopathologic diagnosis.  
23  
24  
25  
26  
27  
28

29  
30 **Introduction**

31  
32 With the prolongation of life span, the incidence of chronic diseases has  
33 been increasing. Dementia is a progressive brain disease, which is one of  
34 the main chronic non-communicable diseases associated with disability  
35 and mortality among elderly individuals. Dementia resulting from  
36 Alzheimer's disease (AD) has catapulted into the public's consciousness  
37 while dementia has many causes—not just Alzheimer's, vascular  
38 dementia (VD) is also considered to be the main types of dementia. Mild  
39 cognitive impairment (MCI) constitutes an intermediate stage between  
40 normal aging and dementia<sup>1</sup>. A widely shared view is that future  
41 treatment strategies need to focus on treatment of the MCI.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

56  
57 Amnestic MCI (aMCI), the rate of this MCI subtype conversion to AD  
58  
59  
60

1  
2  
3  
4 has been reported to be 10% to 15% annually, also the research spotlight  
5  
6 has turned its to be the predementia stage of AD, so it is likely to be the  
7  
8 clinical transition stage of AD<sup>2 3</sup>, and vascular MCI (VaMCI) is  
9  
10 considered to be the early stage of VD<sup>4 5</sup>. The pathogenesis of the two  
11  
12 diseases are different, the aMCI is considered to be neurodegenerative  
13  
14 disease caused by the endogenous neuronal factors such as tau and  
15  
16 amyloid pathology<sup>6</sup> while VaMCI is caused by vascular diseases such as  
17  
18 infarcts or profuse white matter (WM) disease<sup>4 7</sup>. A study has  
19  
20 demonstrated that the hippocampus structure is different in aMCI and  
21  
22 VaMCI<sup>8</sup>. But what about other parts of the brain hasn't been detected.  
23  
24 Both VaMCI and aMCI are associated with deficits in multiple cognitive  
25  
26 domains, with the same chief complaints in memory deficits<sup>9 10</sup>. And by  
27  
28 using neuropsychological tests, previous study has observed the mode of  
29  
30 memory deficit in aMCI and VaMCI is also different<sup>10</sup>. A considerable  
31  
32 body of literature has concluded that patients with VaMCI generally  
33  
34 shows more impairment in semantic memory, executive/attentional  
35  
36 functioning, and visual-spatial and perceptual skills, whereas the clinical  
37  
38 picture of AD is characterized by deficits in episodic memory<sup>4 11 12</sup>. Under  
39  
40 some specific neuropsychological tests, they may have different  
41  
42 performances. However, few studies have examined the relationship  
43  
44 between these two kinds of MCI in their brain structural and cognitive  
45  
46 behavior. If it can be clear which will turn into what type of dementia in  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 patients with cognitive impairment stage, it may be helpful to the  
5  
6 understanding of the mechanism of the two MCI.  
7

8  
9 According to previous publications, aMCI and VaMCI are considered to  
10  
11 be a kind of “disconnection syndrome”<sup>13 14</sup>. By applying the structural  
12  
13 magnetic resonance imaging (sMRI), resting state functional magnetic  
14  
15 resonance (fMRI) and diffusion tensor magnetic resonance imaging (DTI)  
16  
17 technology, we could comprehensive analysis comparison of brain  
18  
19 structure and function in patients with aMCI and VaMCI directly and  
20  
21 noninvasively. Previous studies have detected the atrophy of brain  
22  
23 volume and abnormal functional connectivity in those MCI patients<sup>15-19</sup>.  
24  
25

26  
27 Previous studies also have detected that the brain structures impaired in  
28  
29 VD seem not consistent with AD, especially in the corpus callosum<sup>20 21</sup>,  
30  
31 but whether they are different in MCI hasn't been detected. Moreover, the  
32  
33 changes in brain structural and function are not completely similar<sup>22-24</sup>.  
34  
35

36  
37 Unlike using a single technique, by using multimodal magnetic resonance,  
38  
39 the brain structure and function can be analyzed omni-directionally and  
40  
41 multi-angularly. By using multimodal magnetic resonance could also  
42  
43 consolidate our understanding of how functional networks interact with  
44  
45 their structural substrates.  
46  
47

48  
49 This project in order to reveal the cognitive impairment disease neural  
50  
51 circuits in the development of the network connection and its change rule.  
52  
53

54  
55 People can further understand the pathogenesis of cognitive impairment,  
56  
57  
58  
59  
60

1  
2  
3  
4 discover the relationship between brain structure, function and cognitive  
5  
6 behavior.  
7

## 8 9 **Methods**

### 10 11 **Subject**

12  
13 A total of 240 right-handed subjects (80 aMCI and 80 VaMCI and 80  
14  
15 normal controls, with age, sex and education matched) will be recruited  
16  
17 from the Neurology Department of Hongqi Hospital of Mudanjiang  
18  
19 Medical University, Heilongjiang, China. All participants will receive  
20  
21 baseline evaluation, including complete sociodemographic and clinical  
22  
23 data collection. Patient histories will be collected from informants,  
24  
25 usually from their spouses or children. The diagnosis for the participants  
26  
27 will be performed by two experienced neurologists, respectively.  
28  
29  
30  
31  
32

33  
34 Ethical approval of this has been obtained from the medical research  
35  
36 ethics committee and institutional review board of Hongqi Hospital of  
37  
38 Mudanjiang Medical University, Heilongjiang, China. The study will be  
39  
40 conducted in accordance with the approved guidelines. Written informed  
41  
42 consent will be obtained from all participants. All participation is based  
43  
44 on written informed consent and the participants will be able to withdraw  
45  
46 from the study at any time.  
47  
48  
49  
50

### 51 52 **Inclusion Criteria**

#### 53 54 55 **Criteria for aMCI**

56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Diagnosis of aMCI was made based on the recent international consensus criteria, which were adapted as follows<sup>1 4 25-27</sup>: 1) subjective cognitive complaints reported by the informant; 2) objective cognitive impairments that do not meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-R, fourth-revised edition) criteria for dementia; 3) normal or near-normal performance of general cognitive functioning and no or minimum impairments in daily life activities; 4) abnormal memory function, documented by extensive neuropsychological evaluation; normal general cognitive function, Clinical Dementia Rating Scale (CDR) score = 0.5; 5) Neuropsychological testing included a Hanchinski ischemic (HIS) score (HIS score  $\leq$  to 4) and Montreal cognitive assessment score (MoCA, Beijing Version)<sup>28</sup>.

### Criteria for VaMCI

Diagnosis of VaMCI depended on the following criteria<sup>1 4 19 28</sup>: 1) subjective cognitive complaints reported by the participant or his/her caregiver; 2) insufficient cognitive impairment to meet the DSM-IV-R criteria for dementia; vascular etiology as follows: cognitive impairment due to subcortical small vessel disease (SIVD) was defined as moderate WM changes (at least 1 region score  $<2$  according to the Wahlund rating scale), and/or multiple lacunar infarcts ( $<2$ ) on brain imaging. And may or not be suggested by minor neurological signs.

1  
2  
3  
4 Neuropsychological testings for aMCI, the MoCA scoring, and HIS  
5  
6 determination ( $HIS \geq 7$ ) were also performed.  
7  
8

### 9 10 **Exclusion Criteria**

11  
12 Participants were excluded if they had the following: 1) psychiatric  
13  
14 disease (eg, depression, Hamilton depression rating scale >20, Center for  
15  
16 Epidemiologic Studies Depression Scale >21), systemic disease or other  
17  
18 neurological disorder, 2) visual or auditory abnormalities, severe aphasia  
19  
20 or palsy that made clinical assessments infeasible; 3) any medical or  
21  
22 psychological conditions that might affect cognitive functioning,  
23  
24 including tranquilizers, anti-anxiolytics, hypnotics, nootropics, and  
25  
26 cholinomimetic agents, 4) inability to undergo brain MRI, 5) insufficient  
27  
28 Mandarin language abilities to complete the assessment.  
29  
30  
31  
32  
33  
34

35  
36 The exclusive criteria for VaMCI also included the following: signs of  
37  
38 large vascular disease, such as cortical, and/or cortico-subcortical, or  
39  
40 non-lacunar territorial infarcts and watershed infarcts or hemorrhages.  
41  
42  
43

### 44 **Neuropsychological Evaluations**

45  
46 All participants received a battery of neuropsychological tests to assess  
47  
48 general mental status and other cognitive domains. These tests included  
49  
50 the CDR scale<sup>1 27</sup>, the Mini-Mental State Examination (MMSE)<sup>29</sup>, the  
51  
52 Montreal Cognitive Assessment (MoCA)<sup>28</sup>, and the Auditory Verbal  
53  
54 Learning Test (AVLT)<sup>30</sup>, Memory and Executive Screening (MES)<sup>31</sup>, trail  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 making test(TMT)<sup>32</sup>, the Stroop color naming condition<sup>33</sup>, Clinical  
5  
6 Dementia Rating scale (CDR), and also Hamilton Depression Scale  
7  
8 (HAMD)<sup>34</sup>. Those tests are used for the purpose of evaluating the global  
9  
10 cognition, memory function, attention, visuospatial skills, processing  
11  
12 speed, executive function, and emotion, respectively.  
13  
14

### 15 16 **Magnetic resonance brain imaging protocol** 17

18  
19 For each participant, conventional brain T1-weighted image (T1WI),  
20  
21 T2-weighted image (T2WI) will be obtained to exclude serious brain  
22  
23 diseases. For inpatients, the data will be collected at Hongqi Hospital of  
24  
25 Mudanjiang Medical University while for outpatients, the T1WI and  
26  
27 T2WI may be acquired from other hospitals. The imaging data for  
28  
29 analyzing will be acquired using a 3.0 T Trio Siemens scanner at Hongqi  
30  
31 Hospital of Mudanjiang Medical University.  
32  
33

### 34 35 **sMRI** 36

37  
38 A high-resolution anatomical images will be acquired using a 3D  
39  
40 magnetization-prepared rapid gradient echo (MP-RAGE) T1-weighted  
41  
42 sequence with the following parameters: TR = 1900 ms, TE = 2.2 ms,  
43  
44 inversion time (TI) = 900 ms, FA = 9°, number of slices = 176, slice  
45  
46 thickness = 1 mm, voxel size = 1 × 1 × 1 mm<sup>3</sup>, and matrix = 256 × 256.  
47  
48 Brain MR images were inspected by an experienced neuroradiologist, and  
49  
50 no gross abnormalities were observed for any subject.  
51  
52

### 53 54 **fMRI** 55 56 57 58 59 60

Using an echo-planar imaging sequence (EPI) with the following parameters: repetition time (TR) = 2000 ms, echo time (TE) = 40 ms, flip angle (FA) = 90°, number of slices = 28, slice thickness = 4 mm, gap = 1 mm, voxel size = 4 × 4 × 4 mm<sup>3</sup>, and matrix = 64 × 64. Participants will be asked to lie quietly in the scanner with their eyes closed during data acquisition. Each scan lasted for 478 s.

### **DTI**

Using an EPI sequence in 32 independent, non-collinear directions of a b-value = 1000 s/mm<sup>2</sup>, and one additional image with no diffusion weighting (b = 0). TR = 11000 ms, TE = 98 ms, flip angle = 90°, field of view (FOV) = 256 mm × 256 mm, imaging matrix = 128 × 128, number of slices = 60, and slice thickness = 2 mm. Three acquisitions will be averaged to increase the signal-to-noise ratio.

### **MRI image analysis**

#### **sMRI data analysis**

Both the cortical reconstruction and morphological features extraction will be obtained by using the FreeSurfer software (<http://surfer.nmr.mgh.harvard.edu/>) with a standard cortical automatic handling protocol. First, create a gray matter (GM) template and normalize the GM to the template. The data will be registered to a standard anatomical template<sup>35</sup>, and the resulting aligned T1 data set will be segmented and converted to Montreal Neurological Institute (MNI)

1  
2  
3  
4 space atlas MNI152 1-mm brain template using the DARTEL toolbox<sup>36</sup>  
5  
6 and corrected for bias-field inhomogeneity. Subsequently, the images will  
7  
8 be skull-stripped using a watershed algorithm<sup>37</sup> then segmented into  
9  
10 subcortical WM and deep GM volumetric structures<sup>38 39</sup>. The initial  
11  
12 tessellation will be constituted by reconstructing the boundary of GM  
13  
14 /WM and the outer cortical surface<sup>40 41</sup>. After that, a series of deformable  
15  
16 procedures will be performed. All reconstructed surfaces will be visually  
17  
18 inspected for gross-anatomical topological defects. Finally, a variety of  
19  
20 morphological features at each vertex on the pial surface will be  
21  
22 computed. The parameters will include the whole GM volume, cortical  
23  
24 thickness, and surface area.  
25  
26  
27  
28  
29

### 30 31 **fMRI data analysis** 32

33  
34 Image preprocessing will be performed by using SPM8  
35  
36 (<http://www.fil.ion.ucl.ac.uk/spm/>) and Data Processing Assistant for  
37  
38 Resting-State fMRI<sup>42</sup>. The preprocessing procedures will be performed  
39  
40 including removal of the first 10 volumes, slice timing, and head motion  
41  
42 correction. All fMRI data will be satisfied the criteria of spatial  
43  
44 movement in any direction < 3 mm or 3° and the subjects will be  
45  
46 demonstrated no significant group differences in the head motion  
47  
48 parameters (i.e, three translation and three rotation parameters). To  
49  
50 normalize the fMRI data spatially, the T1 data used in sMRI will be  
51  
52 normalized to the mean functional data, and then segmented and  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 transformed into MNI152 space using the DARTEL toolbox<sup>36 43</sup>, and a  
5  
6 group template will be generated. Next, the motion corrected functional  
7  
8 volumes will be specially normalized to the group template using the  
9  
10 transfer parameter estimated by DARTEL segmentation and resampled to  
11  
12 3 mm isotropic voxels. Further, the functional images will be spatially  
13  
14 smoothed with a 4 mm Gaussian kernel. The linear detrend and temporal  
15  
16 bandpass filtering (0.01 – 0.08 Hz) will be performed to reduce the  
17  
18 influences of low frequency drift and high-frequency physiological noise.  
19  
20 Finally, several nuisance signals will be regressed out from the data,  
21  
22 including the six motion parameters, the global, the WM, and the  
23  
24 cerebrospinal fluid signals. Functional connectivity (FC) analysis is using  
25  
26 DPARSF software (<http://www.restfmri.net/forum/DPARSF>).  
27  
28

29  
30 To perform the whole-brain resting-state FC (rsFC) analysis, Pearson's  
31  
32 correlations between the time courses of any pairs of voxels will be  
33  
34 computed, resulting in a whole-brain connectivity matrix for each  
35  
36 participant. This procedure will be limited within a GM mask, which was  
37  
38 usually generated by a specific thresholding (previous cutoff = 0.2) the  
39  
40 mean map of all GM maps involving all subjects without cerebellum.  
41  
42 These individual correlation matrices will then be transformed as a  
43  
44 z-score matrix by using Fisher's r-to-z transformation to improve  
45  
46 normality. Then, the FC strength (FCS) as the sum of the connections  
47  
48 between a given voxel and all other GM voxels. This computation will be  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 conservatively restricted to connections with a correlation coefficient,  
5  
6 which could eliminate the weak correlations possibly arising from noise.  
7  
8  
9

### 10 11 **DTI data analysis**

12  
13 DTI data processing will be carried out using FMRIB Software Library  
14 software (FSL, [http:// www.fmrib.ox.ac.uk/fsl](http://www.fmrib.ox.ac.uk/fsl))<sup>44</sup>. Initially, eddy current  
15 correction will be run to correct gradient-coil distortions and small-head  
16 motions using affine registration to a reference image (b0 volume). The  
17 brain voxels of DTI data will be extracted using the Brain Extraction Tool  
18 (BET). The maps of diffusion tensor parameters including fractional  
19 anisotropy (FA), axial diffusivity (DA), radial diffusivity (DR), and mean  
20 diffusivity (MD) will be calculated using DTI-FIT tool, which fits a  
21 diffusion tensor model to diffusion-weighted images for each voxel.  
22  
23 Voxel-wise statistical analysis of the FA, DA, DR, and MD data will be  
24 performed for regional differences using tract-based spatial statistics  
25 (TBSS). TBSS is a whole-brain voxel-wise analysis method. Then, the  
26 FSL's nonlinear image registration algorithm will be used, all subjects'  
27 FA maps will be aligned into a 1×1×1 mm<sup>3</sup> standard Montreal  
28 Neurological MNI 152 space. The target template will be the  
29 FMRIB58\_FA ([http://www.fmrib.ox.ac.uk/fsl/data/FMRIB58\\_FA](http://www.fmrib.ox.ac.uk/fsl/data/FMRIB58_FA)). Then  
30 a mean FA image will be created by averaging the aligned FA maps. The  
31 mean FA image will be thinned to build a mean FA skeleton representing  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 the center of all tracts common to all participants in the study. Each  
5  
6 subject's aligned FA data will be projected onto the FA skeleton to obtain  
7  
8 their FA skeletons and deformation matrixes. With the deformation  
9  
10 matrixes, the skeletonized DA, DR, and MD maps will be created by the  
11  
12 `tbss_non_FA` tool. The skeletonized FA, DA, DR, and MD map images  
13  
14 will be subsequently fed to statistical analysis.  
15  
16  
17

### 18 **Statistics**

19  
20 Repeated measures analysis of variance (ANOVA) will be performed to  
21  
22 compare the global differences across the 3 groups, with follow-up post  
23  
24 hoc analyses performed as needed to explain the main effects and  
25  
26 interactions.  
27  
28  
29

30  
31 A multivariate analysis of covariance (MANCOVA) will be conducted  
32  
33 with different kinds of MCI as the independent variable, each brain  
34  
35 volume as a dependent variable, and with age and gender as covariates to  
36  
37 analyze differences in brain volume by different kinds of MCI. In  
38  
39 addition, Pearson correlations (two-tailed) will be used to investigate  
40  
41 correlations between neuropsychological test scores and GM volume,  
42  
43 cortical thickness, and surface area.  
44  
45  
46  
47

48  
49 A general linear model with multivariate ANOVA (MANOVA) with post  
50  
51 hoc test Bonferroni correction was performed to compare the FA, MD,  
52  
53 DA, and DR of each tract between the groups. SPSS (version 20; SPSS  
54  
55 Inc., Cary, NC) was used for this statistical analysis.  
56  
57  
58  
59  
60

1  
2  
3  
4 A one-way analysis of covariance (ANCOVA) will also be performed to  
5  
6 determine the main effect of groups on FCS, with age and gender as  
7  
8 covariates, followed by two-sample t-tests post hoc analyses. The  
9  
10 two-sample t-tests post hoc analyses will be fulfilled within the regions  
11  
12 showing significant group effects. All the cluster sizes were determined  
13  
14 by Monte Carlo simulations<sup>45</sup> using the REST AlphaSim utility<sup>46</sup>.  
15  
16

17  
18 The two-sample t-tests will be performed on the rsFC maps for each seed,  
19  
20 with age and gender as covariates. The significant level was set at  $P <$   
21  
22  $0.05$  with a cluster size of  $1350 \text{ mm}^3$ , corresponding to a corrected  $P <$   
23  
24  $0.05$ . The analysis mask will be generated by selecting the voxels that  
25  
26 may have a significant positive rsFC in any of the two groups. To  
27  
28 investigate the relationship between the brain function, structure and  
29  
30 cognitive behavior, a general linear model analysis (dependent variable:  
31  
32 for function: FCS; for structure: FA, MD, DA, and DR; independent  
33  
34 variable: clinical variables, including MMSE, MoCA, AVLT-immediate  
35  
36 recall, AVLT-delayed recall, and AVLT-delayed recognition, MES and  
37  
38 TMT) will be calculated separately.  
39  
40  
41  
42  
43  
44

#### 45 46 **Association between neuroimage and neuropsychological** 47 48 **performance**

49  
50 Analysis the interaction between the parameters acquired by multimodal  
51  
52 magnetic resonance and cognition measures.  
53  
54

55  
56 The scheme of the current prospective trial is described in Fig. 1  
57  
58  
59  
60



## Discussion

In previous studies, the researchers usually focus on the differences between patients and normal elders, little pays attention to the differences between the similar diseases. At the stage of dementia, the WM microstructure in corpus callosum especially in forceps minor has been detected different between VD and AD<sup>20</sup>. While it is uncertain that the differences took place in the stage of dementia or earlier. In spite that the mode of memory deficit in aMCI and VaMCI is also different<sup>10</sup>, there is still lack of evidence to compare the relationship between those abnormal cognitive behaviors and brain structure and function. So it is meaningful to use multimodal magnetic resonance to observe the neuroimage in the two subtypes of MCI.

Some limitations have to be took into account about this study. First, the trial is just an observational study without follow up so whether would they convert to AD or VD in the future is uncertain. Therefore, we will plan to apply a follow-up to track the dynamic evolution of these patients. Second, our hospital is a primary hospital, we don't have a PET to raise the precision of diagnosis. But the diagnosis of the two groups follow the criteria for the diseases critically to make the diagnosis as precisely as possible. And we will plan to gather the blood and cerebrospinal fluid in our future designs.

The purpose for this study is to find out the differences in neuroimaging



1  
2  
3  
4 between aMCI and VaMCI and exploring the possible mechanism of the  
5  
6 cognitive disorders in the two diseases. Moreover, to provide scientific  
7  
8 diagnosis evidence for different subtypes of MCI.  
9

### 10 11 **Consent for publication**

12  
13  
14 Written consent is obtained from each subject before publishing in this  
15  
16 study.  
17

### 18 19 **Availability of data and material**

20  
21 Not applicable.  
22

### 23 24 **Funding**

25  
26 Study Funded by the National Natural Science Foundation of China  
27  
28 (Grant No. 81301188)  
29

### 30 31 **Author Contributions**

32  
33 All authors participated in the design of the study. YY drafted and revised  
34  
35 the manuscript. WNZ revised the work critically for important intellectual  
36  
37 content. SOL revised the work critically for important intellectual content.  
38  
39 YCH is the final approval of the version published. All authors read and  
40  
41 approved the final manuscript.  
42  
43  
44

### 45 46 **Competing interests**

47  
48 All authors report no competing interests.  
49

### 50 51 **References**

- 52  
53 1. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med*  
54 2004;256(3):183-94.  
55  
56 2. Hussain H. Conversion from subtypes of mild cognitive impairment to Alzheimer  
57 dementia. *Neurology* 2007;68(4):409-09.  
58  
59  
60

3. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. *Arch Neurol* 2001;58(12):1985-92.
4. Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. *Alzheimer Dis Assoc Disord* 2014;28(3):206-18.
5. Jin-zhou T, Heng-ge X, Bin Q, et al. Guidelines for the Diagnosis of Vascular Mild Cognitive Impairment in China. *Chinese Journal of Internal Medicine* 2016;55(3):249-56.
6. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. *Nat Cell Biol* 2004;6(11):1054-61.
7. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. *Stroke* 2011;42(9):2672-713.
8. Li X, Li D, Li Q, et al. Hippocampal subfield volumetry in patients with subcortical vascular mild cognitive impairment. *Scientific Reports* 2016;6.
9. Parikh PK, Troyer AK, Maione AM, et al. The Impact of Memory Change on Daily Life in Normal Aging and Mild Cognitive Impairment. *Gerontologist* 2015;Epub ahead of print.
10. Zhou A, Jia J. Different cognitive profiles between mild cognitive impairment due to cerebral small vessel disease and mild cognitive impairment of Alzheimer's disease origin. *Journal of the International Neuropsychological Society* 2009;15(06):898.
11. Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. *J Neurol Neurosurg Psychiatry* 2004;75(1):61-71.
12. Tomadesso C, Perrotin A, Mutlu J, et al. Brain structural, functional, and cognitive correlates of recent versus remote autobiographical memories in amnesic Mild Cognitive Impairment. *Neuroimage Clin* 2015;8:473-82.
13. Nowrangi MA, Lyketsos CG, Leoutsakos JM, et al. Longitudinal, region-specific course of diffusion tensor imaging measures in mild cognitive impairment and Alzheimer's disease. *Alzheimers Dement* 2013;9(5):519-28.
14. O'Sullivan M. Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosis. *Journal of Neurology, Neurosurgery & Psychiatry* 2004;75(3):441-47.
15. Bai F, Xie C, Watson DR, et al. Aberrant hippocampal subregion networks associated with the classifications of aMCI subjects: a longitudinal resting-state study. *PLoS One* 2011;6(12):e29288.
16. Liu J, Yin C, Xia S, et al. White matter changes in patients with amnesic mild cognitive impairment detected by diffusion tensor imaging. *PLoS One* 2013;8(3):e59440.
17. Li X, Li D, Li Q, et al. Hippocampal subfield volumetry in patients with subcortical vascular mild cognitive impairment. *Sci Rep* 2016;6:20873.
18. Lin L, Xue Y, Duan Q, et al. Microstructural White Matter Abnormalities and

- Cognitive Dysfunction in Subcortical Ischemic Vascular Disease: an Atlas-Based Diffusion Tensor Analysis Study. *J Mol Neurosci* 2015;56(2):363-70.
19. Yi L, Wang J, Jia L, et al. Structural and functional changes in subcortical vascular mild cognitive impairment: a combined voxel-based morphometry and resting-state fMRI study. *PLoS One* 2012;7(9):e44758.
  20. Zarei M, Damoiseaux JS, Morgese C, et al. Regional white matter integrity differentiates between vascular dementia and Alzheimer disease. *Stroke* 2009;40(3):773-9.
  21. Fu JL, Zhang T, Chang C, et al. The value of diffusion tensor imaging in the differential diagnosis of subcortical ischemic vascular dementia and Alzheimer's disease in patients with only mild white matter alterations on T2-weighted images. *Acta Radiol* 2012;53(3):312-7.
  22. Bai F, Shu N, Yuan Y, et al. Topologically convergent and divergent structural connectivity patterns between patients with remitted geriatric depression and amnesic mild cognitive impairment. *J Neurosci* 2012;32(12):4307-18.
  23. Zhang J, Wang J, Wu Q, et al. Disrupted brain connectivity networks in drug-naive, first-episode major depressive disorder. *Biol Psychiatry* 2011;70(4):334-42.
  24. Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. *Nat Rev Neurosci* 2009;10(3):186-98.
  25. Bowler JV. Modern concept of vascular cognitive impairment. *British Medical Bulletin* 2007;83(1):291-305.
  26. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. *J Neural Transm Suppl* 2000;59:23-30.
  27. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology* 1993;43(11):2412-4.
  28. Lu J, Li D, Li F, et al. Montreal Cognitive Assessment in Detecting Cognitive Impairment in Chinese Elderly Individuals: A Population-Based Study. *Journal of Geriatric Psychiatry and Neurology* 2012;24(4):184-90.
  29. Zhang Z, Hong X, Hui LI. The minimal state examination in the Chinese residents population aged 55 years and over in the urban and rural areas of Beijing. *Chinese Journal of Neurology* 1999;03:149-53.
  30. Delis D. C KJHK. California Verbal Learning Test: Adult Version Manual. San Antonio, Tex, USA: The Psychological Corporation, 1987.
  31. Guo QH, Zhou B, Zhao QH, et al. Memory and Executive Screening (MES): a brief cognitive test for detecting mild cognitive impairment. *BMC Neurol* 2012;12:119.
  32. Spreen O, Strauss E. A compendium of neuropsychological tests: Administration, norms, and commentary (2nd ed.). 1998.
  33. Golden CJ. A Manual for the Clinical and Experimental Use of the Stroop Color and Word Test. Stoelting 1978.
  34. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960;23:56-62.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
35. Talairach JJ, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain.3-Dimensional Proportional System: An Approach to Cerebral Imaging. 1988.
36. Ashburner J. A fast diffeomorphic image registration algorithm. *Neuroimage* 2007;38(1):95-113.
37. Ségonne F, Dale AM, Busa E, et al. A hybrid approach to the skull stripping problem in MRI. *Neuroimage* 2004;22(3):1060-75.
38. Fischl B, Salat DH, Busa E, et al. Whole Brain Segmentation : Automated Labeling of Neuroanatomical Structures in the Human Brain. *Neuron* 2002;volume 33(3):341-55(15).
39. Fischl B, Van dKA, Destrieux C, et al. Automatically parcellating the human cerebral cortex. *Cerebral Cortex* 2004;14(1):11-22.
40. Dale AM, Fischl B, Sereno MI. Cortical Surface-Based Analysis ☆ : I. Segmentation and Surface Reconstruction. *Neuroimage* 1999;9(2):179-94.
41. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. *Proceedings of the National Academy of Sciences of the United States of America* 2000;97(20):11050-5.
42. Chao-Gan Y, Yu-Feng Z. DPARSF: A MATLAB Toolbox for "Pipeline" Data Analysis of Resting-State fMRI. *Front Syst Neurosci* 2010;4:13.
43. Chau W, McIntosh AR. The Talairach coordinate of a point in the MNI space: how to interpret it. *Neuroimage* 2005;25(2):408-16.
44. Jenkinson M, Beckmann CF, Behrens TE, et al. FSL. *Neuroimage* 2012;62(2):782-90.
45. Ledberg A, Akerman S, Roland PE. Estimation of the probabilities of 3D clusters in functional brain images. *Neuroimage* 1998;8(2):113-28.
46. Song XW, Dong ZY, Long XY, et al. REST: a toolkit for resting-state functional magnetic resonance imaging data processing. *PLoS One* 2011;6(9):e25031.

1  
2  
3 Fig 1 Flowchart of the current prospective diagnostic trial.

4 80 subjects who are diagnosed as amnesic mild cognitive impairment (aMCI) and 80  
5 vascular mild cognitive impairment (VaMCI) and 80 age, gender and education  
6 matched normal controls (NC) will go through a full neuropsychological tests which  
7 will include mini-mental state examination (MMSE), Montreal Cognitive Assessment  
8 (MoCA), Auditory Verbal Learning Test (AVLT), Memory and Executive Screening  
9 (MES), trail making test(TMT), the Stroop color naming condition, Clinical Dementia  
10 Rating scale (CDR) and neuroimage tests contain sMRI, DTI and fMRI. FA,  
11 fractional anisotropy; axial diffusivity, DA; DR, radial diffusivity; MD, mean  
12 diffusivity.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig 1 Flowchart of the current prospective diagnostic trial 80 subjects who are diagnosed as amnesic mild cognitive impairment (aMCI) and 80 vascular mild cognitive impairment (VaMCI) and 80 age, gender and education matched normal controls (NC) will go through a full neuropsychological tests which will include mini-mental state examination (MMSE), Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Memory and Executive Screening (MES), trail making test(TMT), the Stroop color naming condition, Clinical Dementia Rating scale (CDR) and neuroimage tests contain sMRI, DTI and fMRI. FA, fractional anisotropy; axial diffusivity, DA; DR, radial diffusivity; MD, mean diffusivity.

144x108mm (300 x 300 DPI)

only

# BMJ Open

## Magnetic Resonance Imaging-based Comparative Study of Different Mild Cognitive Impairment Subtypes: Protocol for an Observational Case-Control Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013432.R2
Article Type:	Protocol
Date Submitted by the Author:	13-Dec-2016
Complete List of Authors:	Yu, Yang; Hongqi Hospital of Mudanjiang Medical University, Department of Neurology Zhao, Weina; Hongqi Hospital of Mudanjiang Medical University, Department of Neurology Li, Siou; Hongqi Hospital of Mudanjiang Medical University, Department of Neurology Yin, Changhao ; Hongqi Hospital of Mudanjiang Medical University, Department of Neurology
<b>Primary Subject Heading</b>:	Neurology
Secondary Subject Heading:	Neurology
Keywords:	Amnesic mild cognitive impairment, Neuropsychological, Neuroimaging techniques, Vascular mild cognitive impairment

SCHOLARONE™  
Manuscripts

Only



Magnetic Resonance Imaging-based Comparative Study of Different  
Mild Cognitive Impairment Subtypes: Protocol for an Observational  
Case-Control Study

Authors: Yang Yu, Weina Zhao, Siou Li, \*Changhao Yin

Corresponding author:

Changhao Yin

Hongqi Hospital of Mudanjiang Medical University

No. 3 TongXiang St., AiMin District, Mudanjiang, Heilongjiang Province,  
157011

yinchanghao7916@sina.com

Yang Yu, Department of Neurology, Hongqi Hospital of Mudanjiang  
Medical University, Mudanjiang, Heilongjiang, China

Weina Zhao, Department of Neurology, Hongqi Hospital of Mudanjiang  
Medical University, Mudanjiang, Heilongjiang, China

Siou Li, Department of Neurology, Hongqi Hospital of Mudanjiang  
Medical University, Mudanjiang, Heilongjiang, China

Word count: 2806

## Abstract

### Introduction:

Amnesic mild cognitive impairment (aMCI) and vascular mild cognitive  
impairment (VaMCI) comprise the two main types of mild cognitive



impairment (MCI). The first condition generally progresses to Alzheimer's disease (AD), whereas the second is likely to develop into vascular dementia (VD). The brain structure and function of MCI patients differ from those of normal elderly individuals. However, whether brain structures or functions differ between these two MCI subtypes has not been studied. This study is designed to analyse brain neuroimages in VaMCI and aMCI patients using multi-modality magnetic resonance imaging (MRI) (structural MRI (sMRI), functional MRI, and diffusion tensor imaging (DTI)).

#### **Methods and analysis:**

In this study, 80 subjects diagnosed with aMCI, 80 subjects diagnosed with VaMCI, and 80 age-, gender-, and education-matched normal controls (NC) will be recruited to the Hongqi Hospital of Mudanjiang Medical University, Heilongjiang, China. All subjects will undergo neuroimaging and neuropsychological evaluations. The primary outcome measures will be 1) microstructural alterations revealed by multimodal MRI scans, including sMRI, resting-state functional MRI (rs-fMRI), and DTI; and 2) a neuropsychological evaluation, including the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Memory and Executive Screening (MES), trail making test (TMT), Stroop colour naming condition, and Clinical Dementia Rating scale (CDR), to evaluate global

cognition, memory function, attention, visuospatial skills, processing speed, executive function, and emotion, respectively.

### **Trial registration:**

Protocol registered on ClinicalTrials.gov (NCT02706210)

**Keywords:** Amnesic mild cognitive impairment, Vascular mild cognitive impairment, Neuropsychological, Neuroimaging techniques,

### **Strengths and limitations of this study**

Comparison of different subtypes of MCI.

Use of a combination of multimodal imaging systems.

Lack of clinicopathological diagnosis.

### **Introduction**

Due to the prolongation of the life span, the incidence of chronic diseases has increased. Dementia is a progressive brain disease and is one of the main chronic non-communicable diseases associated with disability and mortality among elderly individuals. Dementia resulting from Alzheimer's disease (AD) has received much public attention. Dementia has many causes in addition to AD. Vascular dementia (VD) is also one of the main types of dementia. Mild cognitive impairment (MCI) constitutes an intermediate stage between normal ageing and dementia<sup>1</sup>. A widely shared view is that future treatment strategies should focus on the treatment of MCI.

The rate of conversion of the amnesic MCI (aMCI) subtype to AD is 10% to 15% annually. Research has focused on the predementia stage of AD, which is likely to be the clinical transition stage of AD<sup>2 3</sup>. In addition, vascular MCI (VaMCI) represents the early stage of VD<sup>4 5</sup>. The pathogenesis of these two diseases differs. aMCI is a neurodegenerative disease caused by endogenous neuronal factors, including tau and amyloid pathology<sup>6</sup>, whereas VaMCI is caused by vascular diseases such as infarcts or profuse white matter (WM) disease<sup>4 7</sup>. One study has demonstrated that the structure of the hippocampus is different in aMCI and VaMCI patients<sup>8</sup>. However, differences in other parts of the brain have not been detected. Both VaMCI and aMCI are associated with deficits in multiple cognitive domains, but they result in the same chief complaints of memory deficits<sup>9 10</sup>. Using neuropsychological tests, a previous study indicated that the mode of memory defects in aMCI and VaMCI patients also differs<sup>10</sup>. A considerable body of literature has concluded that VaMCI patients generally exhibit greater impairment of semantic memory, executive/attentional functioning, and visual-spatial and perceptual skills, whereas the clinical condition of AD is characterized by deficits in episodic memory<sup>4 11 12</sup>. Patients with these conditions may exhibit different performances on specific neuropsychological tests. However, few studies have examined the relationship between these two types of MCI regarding brain structure

and cognitive behaviour. Determining the conditions that will result in different types of dementia in patients with cognitive impairment may be helpful for understanding the mechanisms of the two forms of MCI.

According to previous publications, both aMCI and VaMCI are types of a “disconnection syndrome”<sup>13 14</sup>. By applying structural magnetic resonance imaging (sMRI), resting-state functional magnetic resonance (fMRI), and diffusion tensor magnetic resonance imaging (DTI) technology, we can comprehensively analyse brain structure and function in aMCI and VaMCI patients directly and noninvasively. Previous studies have detected atrophy of brain volume and abnormal functional connectivity in MCI patients<sup>15-19</sup>, along with brain structure impairment in VD that is not consistent with AD, especially in the corpus callosum<sup>20 21</sup>. However, whether these structures differ in various types of MCI has not been determined. Moreover, the changes in brain structure and function are not completely similar<sup>22-24</sup>. In contrast to using a single technique, the brain structure and function can be analysed in an omni-directional and multi-angular manner using multimodal magnetic resonance. The use of multimodal magnetic resonance could also consolidate our understanding of how functional networks interact with their structural substrates.

This project seeks to reveal neural circuits involved in the development of network connections and changes that occur in the context of diseases involving cognitive impairment. We seek to further understand the

pathogenesis of cognitive impairment and discover the relationship between brain structure, function, and cognitive behaviour.

## Methods

### Subjects

A total of 240 right-handed subjects (80 aMCI patients, 80 VaMCI patients, and 80 normal age-, sex-, and education-matched controls) will be recruited from the Neurology Department of Hongqi Hospital of Mudanjiang Medical University, Heilongjiang, China. All participants will undergo a baseline evaluation, including complete sociodemographic and clinical data collection. Patient histories will be collected from informants, typically from their spouses or children. Two experienced neurologists will perform the diagnosis of the participants.

### Inclusion Criteria

#### Criteria for aMCI

The diagnosis of aMCI will be based on the recent international consensus criteria as follows<sup>1 25</sup>: 1) subjective cognitive complaints reported by the informant; 2) objective cognitive impairments that do not meet the Diagnostic and Statistical Manual of Mental Disorders (DSM- $\square$ ) criteria for dementia; 3) normal or near-normal performance of general cognitive functioning and no or minimum impairments in daily life activities; 4) abnormal memory function documented by an extensive

neuropsychological evaluation, normal general cognitive function, and a Clinical Dementia Rating scale (CDR) score = 0.5<sup>26</sup>; and 5) neuropsychological testing including a Hachinski ischaemic score (HIS)  $\leq 4$  and Montreal Cognitive Assessment score (MoCA, Beijing Version)<sup>27</sup>.

### Criteria for VaMCI

The diagnosis of VaMCI will be based on the Diagnostic Criteria for Vascular Cognitive Disorders (VCD)<sup>45</sup> and DSM- $\square$  criteria; and vascular aetiology as follows: cognitive impairment due to subcortical small vessel disease (SIVD)<sup>28</sup> defined as moderate WM changes (at least 1 region score  $< 2$  according to the Wahlund rating scale) or multiple lacunar infarcts ( $< 2$ ) on brain imaging that may or may not be suggested by minor neurological signs. Neuropsychological tests for aMCI, MoCA scoring, and HIS determination (HIS  $\geq 7$ ) will also be performed.

### Exclusion Criteria

Participants with the following conditions will be excluded: 1) psychiatric disease (e.g., depression, Hamilton depression rating scale (HAMD)  $> 20$ , Center for Epidemiologic Studies Depression Scale  $> 21$ ), systemic disease, or other neurological disorders; 2) visual or auditory abnormalities, severe aphasia, or palsy that renders clinical assessments infeasible; 3) any medical or psychological conditions that might affect

cognitive functioning, including tranquilizers, anti-anxiolytics, hypnotics, nootropics, and cholinomimetic agents; 4) inability to undergo brain MRI, such as claustrophobia; 5) insufficient Mandarin language abilities to complete the assessment; and 6) marked head-motion according to the MRI image.

The exclusion criteria for VaMCI will also include the following: signs of large vascular disease, such as cortical or cortico-subcortical or non-lacunar territorial infarcts and watershed infarcts or haemorrhages.

### **Neuropsychological Evaluations**

All participants will receive a battery of neuropsychological tests to assess general mental status and other cognitive domains. These tests will include the CDR scale<sup>1 26</sup>, Mini-Mental State Examination (MMSE)<sup>29</sup>, MoCA<sup>27</sup>, Auditory Verbal Learning Test (AVLT)<sup>30</sup>, Memory and Executive Screening (MES)<sup>31</sup>, trail making test (TMT)<sup>32</sup>, Stroop colour naming condition<sup>33</sup>, CDR, and HAMD<sup>34</sup>. These tests will be used to evaluate global cognition, memory function, attention, visuospatial skills, processing speed, executive function, and emotion, respectively.

### **Magnetic Resonance Brain Imaging Protocol**

For each participant, conventional brain T1-weighted image (T1WI) and T2-weighted image (T2WI) data will be obtained to exclude serious brain diseases. For inpatients, the data will be collected at Hongqi Hospital of

Mudanjiang Medical University. For outpatients, the T1WI and T2WI data may be acquired from other hospitals. The imaging data used for analysis will be acquired using a 3.0 T Trio Siemens scanner (Magnetom Tim Trio; Siemens Medical Solutions, Erlangen, Germany) at Hongqi Hospital of Mudanjiang Medical University.

### **sMRI**

High-resolution anatomical images will be acquired using a 3D magnetization-prepared rapid gradient echo (MP-RAGE) T1-weighted sequence with the following parameters: repetition time (TR) = 1900 ms, echo time (TE) = 2.2 ms, inversion time (TI) = 900 ms, flip angle (FA) = 9°, number of slices = 176, slice thickness = 1 mm, voxel size = 1 × 1 × 1 mm<sup>3</sup>, and matrix = 256 × 256. Brain magnetic resonance images will be inspected by an experienced neuroradiologist to determine the presence of gross abnormalities.

### **fMRI**

An echo-planar imaging (EPI) sequence with the following parameters will be used: TR = 2000 ms, TE = 40 ms, FA = 90°, number of slices = 28, slice thickness = 4 mm, gap = 1 mm, voxel size = 4 × 4 × 4 mm<sup>3</sup>, and matrix = 64 × 64. Participants will be asked to lie quietly in the scanner with their eyes closed during data acquisition. Each scan will last for 478 s.

### **DTI**



An EPI sequence will be used in 32 independent, non-collinear directions with a b-value of  $1000 \text{ s/mm}^2$ , and one additional image with no diffusion weighting ( $b = 0$ ) will be acquired (TR = 11,000 ms, TE = 98 ms, FA =  $90^\circ$ , field of view (FOV) =  $256 \text{ mm} \times 256 \text{ mm}$ , imaging matrix =  $128 \times 128$ , number of slices = 60, and slice thickness = 2 mm). Three acquisitions will be averaged to increase the signal-to-noise ratio.

## **MRI Data Analysis**

### **sMRI Data Analysis**

Both the cortical reconstruction and morphological feature extraction will be conducted using FreeSurfer software (<http://surfer.nmr.mgh.harvard.edu/>) with a standard cortical automatic handling protocol. First, a grey matter (GM) template will be created, and the GM will be normalized to the template. The data will be registered to a standard anatomical template<sup>35</sup>, and the resulting aligned T1 data set will be segmented and converted to a Montreal Neurological Institute (MNI) space atlas MNI152 1-mm brain template using the DARTEL toolbox<sup>36</sup> and corrected for bias-field inhomogeneity. Subsequently, the images will be skull-stripped using a watershed algorithm<sup>37</sup> then segmented into subcortical WM and deep GM volumetric structures<sup>38 39</sup>. The initial tessellation will be conducted anatomical topological defects. Finally, a variety of morphological features at each vertex on the pial surface will be computed. The parameters will include the entire GM

1  
2  
3  
4 volume, cortical thickness, and surface area.

### 6 **fMRI Data Analysis**

8 Image pre-processing will be performed using SPM8  
9 (http://www.fil.ion.ucl.ac.uk/spm/) and the Data Processing Assistant for  
10 Resting-State fMRI<sup>40</sup>. Pre-processing procedures will be performed,  
11 including removal of the first 10 volumes, slice timing, and head motion  
12 correction. All fMRI data will satisfy the criteria of spatial movement in  
13 any direction  $< 3$  mm or  $3^\circ$ , and the subjects will exhibit no significant  
14 group differences in the head motion parameters (i.e., three translation  
15 and three rotation parameters). To spatially normalize the fMRI data, the  
16 T1 data used in sMRI will be normalized to the mean functional data,  
17 segmented, and transformed into MNI152 space using the DARTEL  
18 toolbox<sup>36 41</sup>, and a group template will be generated. Next, the motion  
19 corrected functional volumes will be specifically normalized to the group  
20 template using the transfer parameter estimated by DARTEL  
21 segmentation and resampled to 3-mm isotropic voxels. Furthermore, the  
22 functional images will be spatially smoothed with a 4-mm Gaussian  
23 kernel. Linear detrend and temporal bandpass filtering (0.01-0.08 Hz)  
24 will be performed to reduce the effects of low-frequency drift and  
25 high-frequency physiological noise. Finally, several nuisance signals will  
26 be regressed from the data, including the six motion parameters and the  
27 global, WM, and cerebrospinal fluid signals. Functional connectivity (FC)  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

analysis will be performed using DPARSF software (<http://www.restfmri.net/forum/DPARSF>).

To perform the whole-brain resting-state FC (rsFC) analysis, Pearson's correlations between the time courses of all pairs of voxels will be computed, resulting in a whole-brain connectivity matrix for each participant. This procedure will be limited within a GM mask, which is typically generated by a specific thresholding (previous cut-off = 0.2) of the mean map of all GM maps involving all subjects without cerebella. These individual correlation matrices will then be transformed as a z-score matrix using Fisher's r-to-z transformation to improve normality. Then, the FC strength (FCS) will be computed as the sum of the connections between a given voxel and all other GM voxels. This computation will be conservatively restricted to connections with a correlation coefficient, which could eliminate the weak correlations possibly arising from noise.

### **DTI Data Analysis**

DTI data processing will be performed using software from the FMRIB Software Library (FSL, <http://www.fmrib.ox.ac.uk/fsl>)<sup>42</sup>. Initially, eddy current corrections will be performed to correct gradient-coil distortions and small head motions using affine registration to a reference image (b0 volume). The brain voxels of DTI data will be extracted using the Brain Extraction Tool (BET). The maps of diffusion tensor parameters,

including fractional anisotropy (FA), axial diffusivity (DA), radial diffusivity (DR), and mean diffusivity (MD), will be calculated using the DTI-FIT tool, which fits a diffusion tensor model to diffusion-weighted images for each voxel. Voxel-wise statistical analysis of the FA, DA, DR, and MD data will be performed for regional differences using tract-based spatial statistics (TBSS), which is a whole-brain voxel-wise analysis method. Then, FSL nonlinear image registration algorithm will be used. FA maps of all subjects will be aligned into a  $1 \times 1 \times 1$  mm<sup>3</sup> standard Montreal Neurological MNI 152 space. The target template will be the FMRIB58\_FA ([http://www.fmrib.ox.ac.uk/fsl/data/FMRIB58\\_FA](http://www.fmrib.ox.ac.uk/fsl/data/FMRIB58_FA)). Then, a mean FA image will be created by averaging the aligned FA maps. The mean FA image will be thinned to build a mean FA skeleton representing the centre of all tracts common to all participants in the study. Each subject's aligned FA data will be projected onto the FA skeleton to obtain their FA skeletons and deformation matrixes. Using the deformation matrixes, skeletonized DA, DR, and MD maps will be created by the `tbss_non_FA` tool. The skeletonized FA, DA, DR, and MD map images will be subsequently subjected to statistical analysis.

### Statistical Analysis

Repeated measures analysis of variance (ANOVA) will be performed to compare the global differences across the 3 groups, with follow-up post hoc analyses performed as needed to explain the main effects and

interactions.

Multivariate analysis of covariance (MANCOVA) will be conducted with the MCI type as the independent variable, each brain volume as a dependent variable, and age and gender as covariates to analyse differences in brain volume by different types of MCI. In addition, Pearson correlations (two-tailed) will be used to investigate correlations between neuropsychological test scores and the GM volume, cortical thickness, and surface area.

A general linear model with multivariate ANOVA (MANOVA) and post hoc Bonferroni correction will be performed to compare the FA, MD, DA, and DR of each tract among the groups. SPSS (version 20; SPSS Inc., Cary, NC) will be used for this statistical analysis.

A one-way analysis of covariance (ANCOVA) will also be performed to determine the main effect of groups on FCS using age and gender as covariates followed by two-sample t-tests for post hoc analyses. The two-sample t-tests post hoc analyses will be conducted within regions exhibiting significant group effects. All the cluster sizes will be determined by Monte Carlo simulations<sup>43</sup> using the REST AlphaSim utility<sup>44</sup>.

The two-sample t-tests will be performed on the rsFC maps for each seed using age and gender as covariates. The significance level will be set at  $P < 0.05$  with a cluster size of  $1350 \text{ mm}^3$ , corresponding to a corrected  $P <$

0.05. The analysis mask will be generated by selecting the voxels that may have a significant positive rsFC in any of the two MCI groups. To investigate the relationship among brain function, structure, and cognitive behaviour, a general linear model analysis (dependent variable for function: FCS; for structure: FA, MD, DA, and DR; independent variables: clinical variables, including MMSE, MoCA, AVLT-immediate recall, AVLT-delayed recall, AVLT-delayed recognition, MES, and TMT scores) will be conducted separately.

### **Association Between Neuroimaging and Neuropsychological Performance**

We will analyse the interaction between the parameters acquired by multimodal magnetic resonance and cognition measures.

A scheme of the current prospective trial is described in Fig. 1

### **Ethics and dissemination**

Ethical approval for this study has been obtained from the Medical Research Ethics Committee and Institutional Review Board of Hongqi Hospital of Mudanjiang Medical University, Heilongjiang, China. The study will be conducted in accordance with the approved guidelines.

Written informed consent will be obtained from all participants, and the participants will be able to withdraw from the study at any time.

### **Discussion**

In previous studies, researchers have typically focused on the differences

1  
2  
3  
4 between patients and normal elderly individuals, and little attention has  
5  
6 been given to the differences between similar diseases. In the late stage of  
7  
8 dementia, the WM microstructure in the corpus callosum, especially in  
9  
10 the forceps minor, exhibits differences in VD and AD patients<sup>20</sup>. However,  
11  
12 the differences that occur in the early stages of dementia are uncertain.  
13  
14 Although the mode of memory defects in aMCI and VaMCI patients is  
15  
16 different<sup>10</sup>, comparisons of the relationship between these abnormal  
17  
18 cognitive behaviours and brain structure and function are lacking. Thus,  
19  
20 use multimodal magnetic resonance to observe neuroimages in the two  
21  
22 subtypes of MCI is relevant.  
23  
24  
25  
26  
27

28  
29 Some limitations of this study should be noted. First, this trial is only an  
30  
31 observational study without follow-up; whether these patients will  
32  
33 convert to AD or VD in the future is uncertain. Therefore, we plan to  
34  
35 conduct follow-up to track the dynamic evolution of these patients.  
36  
37 Second, our facility is a primary hospital. We do not have a PET scanner  
38  
39 to increase the precision of diagnosis. However, the diagnosis of the two  
40  
41 groups will strictly follow the criteria for the diseases to allow the  
42  
43 diagnosis to be as precise as possible. We plan to collect blood and  
44  
45 cerebrospinal fluid in future studies.  
46  
47  
48  
49

50  
51 The purpose for this study is to identify differences in neuroimaging  
52  
53 results between aMCI and VaMCI patients and to explore the possible  
54  
55 mechanisms of cognitive disorders in the two diseases. Moreover, we  
56  
57  
58  
59  
60



seek to provide scientific evidence for the diagnosis of different subtypes of MCI.

### Consent for Publication

Written consent will be obtained from each subject before publishing this study.

### Availability of Data and Material

Not applicable.

### References

1. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med* 2004;**256**(3):183-94.
2. Hussain H. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. *Neurology* 2007;**68**(4):409-09.
3. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. *Arch Neurol* 2001;**58**(12):1985-92.
4. Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. *Alzheimer Dis Assoc Disord* 2014;**28**(3):206-18.
5. Jin-zhou T, Heng-ge X, Bin Q, et al. Guidelines for the Diagnosis of Vascular Mild Cognitive Impairment in China. *Chinese Journal of Internal Medicine* 2016;**55**(3):249-56.
6. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. *Nat Cell Biol* 2004;**6**(11):1054-61.
7. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. *Stroke* 2011;**42**(9):2672-713.
8. Li X, Li D, Li Q, et al. Hippocampal subfield volumetry in patients with subcortical vascular mild cognitive impairment. *Scientific Reports* 2016;**6**.
9. Parikh PK, Troyer AK, Maione AM, et al. The Impact of Memory Change on Daily Life in Normal Aging and Mild Cognitive Impairment. *Gerontologist* 2015;**Epub ahead of print**.
10. Zhou A, Jia J. Different cognitive profiles between mild cognitive impairment due to cerebral small vessel disease and mild cognitive impairment of Alzheimer's disease origin. *Journal of the International Neuropsychological Society* 2009;**15**(06):898.
11. Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. *J Neurol Neurosurg Psychiatry* 2004;**75**(1):61-71.
12. Tomadesso C, Perrotin A, Mutlu J, et al. Brain structural, functional, and cognitive correlates of recent versus remote autobiographical memories in amnesic Mild Cognitive Impairment. *Neuroimage Clin* 2015;**8**:473-82.
13. Nowrangi MA, Lyketsos CG, Leoutsakos JM, et al. Longitudinal, region-specific course of diffusion tensor imaging measures in mild cognitive impairment and Alzheimer's disease. *Alzheimers*



- Dement 2013;**9**(5):519-28.
14. O'Sullivan M. Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosis. *Journal of Neurology, Neurosurgery & Psychiatry* 2004;**75**(3):441-47.
  15. Bai F, Xie C, Watson DR, et al. Aberrant hippocampal subregion networks associated with the classifications of aMCI subjects: a longitudinal resting-state study. *PLoS One* 2011;**6**(12):e29288.
  16. Liu J, Yin C, Xia S, et al. White matter changes in patients with amnesic mild cognitive impairment detected by diffusion tensor imaging. *PLoS One* 2013;**8**(3):e59440.
  17. Li X, Li D, Li Q, et al. Hippocampal subfield volumetry in patients with subcortical vascular mild cognitive impairment. *Sci Rep* 2016;**6**:20873.
  18. Lin L, Xue Y, Duan Q, et al. Microstructural White Matter Abnormalities and Cognitive Dysfunction in Subcortical Ischemic Vascular Disease: an Atlas-Based Diffusion Tensor Analysis Study. *J Mol Neurosci* 2015;**56**(2):363-70.
  19. Yi L, Wang J, Jia L, et al. Structural and functional changes in subcortical vascular mild cognitive impairment: a combined voxel-based morphometry and resting-state fMRI study. *PLoS One* 2012;**7**(9):e44758.
  20. Zarei M, Damoiseaux JS, Morgese C, et al. Regional white matter integrity differentiates between vascular dementia and Alzheimer disease. *Stroke* 2009;**40**(3):773-9.
  21. Fu JL, Zhang T, Chang C, et al. The value of diffusion tensor imaging in the differential diagnosis of subcortical ischemic vascular dementia and Alzheimer's disease in patients with only mild white matter alterations on T2-weighted images. *Acta Radiol* 2012;**53**(3):312-7.
  22. Bai F, Shu N, Yuan Y, et al. Topologically convergent and divergent structural connectivity patterns between patients with remitted geriatric depression and amnesic mild cognitive impairment. *J Neurosci* 2012;**32**(12):4307-18.
  23. Zhang J, Wang J, Wu Q, et al. Disrupted brain connectivity networks in drug-naive, first-episode major depressive disorder. *Biol Psychiatry* 2011;**70**(4):334-42.
  24. Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. *Nat Rev Neurosci* 2009;**10**(3):186-98.
  25. Bowler JV. Modern concept of vascular cognitive impairment. *British Medical Bulletin* 2007;**83**(1):291-305.
  26. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology* 1993;**43**(11):2412-4.
  27. Lu J, Li D, Li F, et al. Montreal Cognitive Assessment in Detecting Cognitive Impairment in Chinese Elderly Individuals: A Population-Based Study. *Journal of Geriatric Psychiatry and Neurology* 2012;**24**(4):184-90.
  28. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. *J Neural Transm Suppl* 2000;**59**:23-30.
  29. Zhang Z, Hong X, Hui LI. The minimental state examination in the Chinese residents population aged 55 years and over in the urban and rural areas of Beijing. *Chinese Journal of Neurology* 1999;**03**:149-53.
  30. Delis D. C KJHK. *California Verbal Learning Test: Adult Version Manual*. San Antonio, Tex, USA: The Psychological Corporation, 1987.
  31. Guo QH, Zhou B, Zhao QH, et al. Memory and Executive Screening (MES): a brief cognitive test for detecting mild cognitive impairment. *BMC Neurol* 2012;**12**:119.

32. Spreen O, Strauss E. A compendium of neuropsychological tests: Administration, norms, and commentary (2nd ed.). 1998.
33. Golden CJ. A Manual for the Clinical and Experimental Use of the Stroop Color and Word Test. Stoelting 1978.
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;**23**:56-62.
35. Talairach JJ, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain.3-Dimensional Proportional System: An Approach to Cerebral Imaging. 1988.
36. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007;**38**(1):95-113.
37. Ségonne F, Dale AM, Busa E, et al. A hybrid approach to the skull stripping problem in MRI. Neuroimage 2004;**22**(3):1060-75.
38. Fischl B, Salat DH, Busa E, et al. Whole Brain Segmentation : Automated Labeling of Neuroanatomical Structures in the Human Brain. Neuron 2002;**volume 33**(3):341-55(15).
39. Fischl B, Van dKA, Destrieux C, et al. Automatically parcellating the human cerebral cortex. Cerebral Cortex 2004;**14**(1):11-22.
40. Chao-Gan Y, Yu-Feng Z. DPARSF: A MATLAB Toolbox for "Pipeline" Data Analysis of Resting-State fMRI. Front Syst Neurosci 2010;**4**:13.
41. Chau W, McIntosh AR. The Talairach coordinate of a point in the MNI space: how to interpret it. Neuroimage 2005;**25**(2):408-16.
42. Jenkinson M, Beckmann CF, Behrens TE, et al. FSL. Neuroimage 2012;**62**(2):782-90.
43. Ledberg A, Akerman S, Roland PE. Estimation of the probabilities of 3D clusters in functional brain images. Neuroimage 1998;**8**(2):113-28.
44. Song XW, Dong ZY, Long XY, et al. REST: a toolkit for resting-state functional magnetic resonance imaging data processing. PLoS One 2011;**6**(9):e25031.

### Author Contributions

All authors participated in the design of the study. YY drafted and revised the manuscript. WNZ and SOL revised the work critically for important intellectual content. YCH provided the final approval of the version published. All authors read and approved the final manuscript.

### Funding Statement

This study is Funded by the National Natural Science Foundation of China (Grant No. 81301188)

### Competing interests

All authors report no competing interests.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Fig. 1. Flowchart of the current prospective diagnostic trial.

Eighty subjects diagnosed with amnesic mild cognitive impairment (aMCI), 80 subjects diagnosed with vascular mild cognitive impairment (VaMCI), and 80 age-, gender-, and education-matched normal controls (NC) will be subjected to full neuropsychological tests, including the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Memory and Executive Screening (MES), trail making test (TMT), Stroop colour naming condition, Clinical Dementia Rating scale (CDR), and neuroimaging tests, including sMRI, DTI, and fMRI. FA, fractional anisotropy; axial diffusivity, DA; DR, radial diffusivity; MD, mean diffusivity.

For peer review only




Fig. 1. Flowchart of the current prospective diagnostic trial.

Eighty subjects diagnosed with amnesic mild cognitive impairment (aMCI), 80 subjects diagnosed with vascular mild cognitive impairment (VaMCI), and 80 age-, gender-, and education-matched normal controls (NC) will be subjected to full neuropsychological tests, including the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Memory and Executive Screening (MES), trail making test (TMT), Stroop colour naming condition, Clinical Dementia Rating scale (CDR), and neuroimaging tests, including sMRI, DTI, and fMRI. FA, fractional anisotropy; axial diffusivity, DA; DR, radial diffusivity; MD, mean diffusivity.

144x108mm (300 x 300 DPI)

